Chongqing Paijin Biotechnology Co Ltd.

Primary objective: To evaluate the efficacy and safety of PN20 for the prevention of CIT in adult patients. Secondary objectives: (1) To evaluate the dosing regimen of PN20 in adult patients with CIT; (2) To evaluate the pharmacodynamic properties of PN20 in adult patients with CIT; (3) To evaluate the pharmacokinetic properties of PN20 in adult patients with CIT; (4) To evaluate the immunogenicity of PN20 in adult patients with CIT. (5) To evaluate the efficacy and safety of PN20 in the treatment of adult patients with CIT.

Primary Objectives: Dose-Escalation Phase (Phase Ib): Evaluate the safety and tolerability of PD5K3 combined with chemotherapy in the treatment of ALL/LBL and determine the maximum tolerated dose (MTD) of PD5K3 in combination with chemotherapy. Dose-Expansion Phase (Phase II): Compare the PK/PD profiles of PD5K3 combined with chemotherapy and pegaspargase combined with chemotherapy in the treatment of ALL/LBL and select a recommended dose for the future.

Main objectives 1. To observe the safety and tolerability of PA5 injection; 2. To determine the maximum tolerated dose (MTD) and recommended dose (RP2D) of PA5 injection for phase II clinical study. Secondary objectives 1. To evaluate the pharmacokinetic (PK) characteristics, pharmacodynamics (PD) and immunogenicity after intravenous infusion of PA5; 2. To observe the preliminary efficacy of PA5 monotherapy in patients with advanced solid tumors.